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Abstract
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B
(RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL)
and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has
been examined in only one prior study.
Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition
(EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER–, n = 386),
matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood
collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT).
Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence
intervals (CIs) were calculated using conditional logistic regression.
Results: The associations between OPG and ER+ and ER– breast cancer differed significantly. Higher concentrations
of OPG were associated with increased risk of ER– breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24–3.02];
ptrend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women
premenopausal at blood collection. Results for ER– disease did not differ by menopausal status at blood collection
(phet = 0.97), and we observed no heterogeneity by HT use at blood collection (phet ≥ 0.43) or age at breast cancer
diagnosis (phet ≥ 0.30).
Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor
subtype. High circulating OPG may represent a novel risk factor for ER– breast cancer.
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Background
Osteoprotegerin (OPG) is a homodimeric glycoprotein
and a member of the tumor necrosis factor (TNF) recep-
tor superfamily [1]. OPG was first characterized as a
negative regulator of bone turnover. Bone homeostasis is
maintained by the interplay between the receptor activator
of nuclear factor kappa-B (RANK), its soluble activation
ligand (RANKL), and OPG. OPG binds RANKL as a
decoy receptor, inhibiting the activation of RANK by
RANKL and preventing the differentiation of bone
marrow precursor (monocyte/macrophage) cells to
osteoclasts — cells that are central in the process of
bone resorption [2].
Besides bone, OPG is expressed in other tissues, in-
cluding the stomach, intestines, skin, liver, heart, lung,
kidney, and breast. This expression across diverse tissue
types indicates that its biologic functions may extend be-
yond bone metabolism. In relation to breast cancer,
OPG was initially investigated as a potential inhibitor of
metastasis-related osteolysis [3, 4]. The RANKL inhibi-
tor denosumab acts to reduce skeletal-related events in
patients with bone metastases. More recent data show
that OPG is also produced in breast tumor cells, and
that it can promote tumor growth and metastasis [5, 6].
In vitro studies suggest that OPG, again acting as a
decoy receptor, also binds to TNF-related apoptosis-
inducing ligand (TRAIL), thereby preventing cancer cell
death via apoptosis [7, 8]. Furthermore, OPG can induce
cell proliferation and angiogenesis through a variety of
cell surface receptors [5, 6].
Besides local expression in many tissue types, OPG is
present in blood. Circulating OPG has been examined in
the context of chronic disease risk, including impaired
glucose tolerance and type 2 diabetes [9], vascular
calcification, atherosclerosis and cardiovascular disease
[10, 11], cancer [12], and overall mortality [10]. However,
to date, only one prospective study has examined the rela-
tionship between circulating OPG and breast cancer risk
[12]. This study observed reduced breast cancer risk
among women with comparatively high OPG concentra-
tions, but given a small number of incident cases (n = 76),
risk by tumor subtypes (e.g., by estrogen (ER) and proges-
terone (PR) receptor status) was not investigated. We pro-
vide the first prospective data on OPG and breast cancer
risk by hormone receptor status, in a large nested case-
control study in the European Prospective Investigation
into Cancer and Nutrition (EPIC) cohort.
Methods
The EPIC cohort was designed to identify risk factors for
cancer [13]. Briefly, between 1992 and 2000 about 520,000
apparently healthy men and women (n = 367,993 women),
from 10 European countries (Denmark, France, Germany,
Greece, Italy, the Netherlands, Norway, Spain, Sweden,
and the United Kingdom), generally between ages 35 and
75 years, enrolled in the study. Detailed dietary, anthropo-
metric, lifestyle, and medical history data were collected
via standardized methods. Blood samples were collected
according to standardized protocols (n = 235,607 women).
Samples for this study were stored centrally under liquid
nitrogen (–196 °C) at the International Agency for
Research on Cancer (IARC), except those from Denmark,
which were stored locally at –150 °C.
Incident cancers were identified through linkages with
regional cancer registries except in France, Germany,
Greece, and Naples (Italy), where follow-up is conducted
by review of health insurance records, contacts with can-
cer and pathology registries, and/or direct contact with
cohort members. Vital status is ascertained through link-
ages with regional and national mortality registries and
active follow-up (Germany and Greece). Details on the
identification and verification of incident breast cancer
cases and collection of hormone receptor status data
were reported previously [14].
Nested case-control study
Case and control selection has been described previously
[15]. Cases and matched controls were women either
pre- or postmenopausal at the time of blood collection,
with no previous diagnosis of invasive cancer (with the
exception of non-melanoma skin cancer) or in situ
breast cancer. Premenopausal women included in this
study were not using oral contraceptives (OCs), whereas
the postmenopausal study population included both hor-
mone therapy (HT) users and non-users. Participants
from Sweden were not included in this investigation,
given the independent studies on breast cancer risk con-
ducted in those centers.
The end of follow-up for this study was the last date
of complete follow-up for both cancer incidence and
vital status (range: 2003–2006, depending on the study
center). All incident cases with ER status available were
included through 2004. After 2004, all newly diagnosed
ER– cases were included, and among postmenopausal
women an equal number of ER+ cases were randomly
selected among cases matching each ER– case for re-
cruitment center.
One control per case was selected among cohort
members who donated a blood sample and who were
alive and free of cancer (except non-melanoma skin can-
cer) at the time of invasive breast cancer diagnosis of the
index case. Controls were matched to cases on recruit-
ment center, age (±3 months), menopausal status, HT
use, fasting status (<3, 3–6, >6 hours), and time of day
(±1 hour) at blood donation. Premenopausal women
were also matched for phase of menstrual cycle (early
follicular, late follicular, periovulatory, early luteal, mid-
luteal, late luteal).
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A total of 2020 case-control sets were initially selected.
After excluding sets in which the case or control was
missing the OPG measurement (n = 7 sets) or had OPG
values identified as outliers (n = 5 sets), a total of 2008
case-control sets remained for analysis. PR status was
available for a total of 74% of cases (n = 1480).
Within-person reproducibility study
The EPIC-Heidelberg cohort was recruited between
1994 and 1998. The EPIC-Heidelberg substudy has been
described previously [16]. Briefly, between 2010 and 2013,
approximately 600 cohort participants (50% women)
provided additional blood samples, with a total of 592
participants providing samples and exposure data at
baseline and 14 and 15 years after recruitment. OPG
was measured in repeat blood samples from 221
women randomly selected from this population to assess
within-person reproducibility over 1 year (between years
14 and 15) and over 14 years (between baseline and year
14) (Additional file 1: Table S1).
Laboratory methods
Serum OPG concentrations were measured in the
Laboratory of the Division of Cancer Epidemiology at
the German Cancer Research Center (DKFZ), using an
electrochemiluminescence assay (MesoScale Diagnostics,
Rockville, MD, USA). Samples from cases and their
matched controls were analyzed in the same analytical
batch, and laboratory personnel were blinded to the
case-control status of the samples. The precision of the
laboratory work was monitored by inclusion of blinded
pooled quality control (QC) samples (two per batch).
Intra-batch coefficients of variation (CVs) were 15%;
inter-batch CVs were 17%.
Serum concentrations of estradiol, estrone, testosterone,
dehydroepiandrosterone sulfate (DHEAS), sex hormone-
binding globulin (SHBG), progesterone, prolactin, and
insulin-like growth factor 1 (IGF-1) were available for sub-
sets of the study population and were assessed as covari-
ates and effect modifiers. Laboratory methods have been
described previously [14, 15, 17, 18].
Statistical analyses
OPG was log2-transformed to obtain an approximately
normal distribution; this transformation allows an estima-
tion of the effect of a doubling of biomarker concentration.
Outliers were evaluated using the extreme Studentized de-
viate many-outlier procedure [19].
Spearman correlations were used to evaluate associa-
tions between OPG and continuous covariates and en-
dogenous hormones; geometric means of OPG were
compared between categories of categorical covariates.
These analyses were restricted to controls and adjusted
for matching factors. OPG was classified into tertiles
based on the distribution in controls. As OPG levels do
not vary significantly by menopausal status, tertile cut-
off points were calculated based on the overall control
population. Conditional logistic regression was used to
estimate the relative risk (RRs) and 95% confidence in-
tervals (CIs). Tests for trend were based on OPG mod-
eled as a continuous variable. OPG concentrations are
known to increase with age; therefore, Spearman corre-
lations were used to examine the reproducibility of the
relative ranking of study subjects over time, comparing
concentrations in samples taken 1 and 14 years apart.
Ages at menarche, menopause, and first full-term
pregnancy (FTP), number of FTPs, and body mass index
(BMI; kg/m2) were included in the multivariable model.
Additional adjustment for lifetime mean alcohol con-
sumption, past oral contraceptive use, breastfeeding, and
smoking status did not materially impact the results
(RRlog2 change <10%).
We evaluated heterogeneity by reproductive and life-
style factors or endogenous hormone levels by compar-
ing models including and excluding interaction terms
using the likelihood ratio test (LRT). Tests for inter-
action were based on continuous, log2-transformed
OPG concentrations. We assessed potential heterogen-
eity by tumor hormone receptor status and age at diag-
nosis (<50 vs. 50+ years) by comparing models assuming
the same association between OPG and breast cancer in
subgroups (e.g., ER+ and ER–) to one assuming different
associations by subgroup using the LRT [20]. We exam-
ined the possibility of non-linearity non-parametrically
with restricted cubic splines [21]. Tests for non-linearity
used the LRT, comparing the model with only the linear
term to the model with the linear and the cubic spline
terms. There was no evidence of deviations from linear-
ity (p > 0.12), with the exception of the association be-
tween OPG and ER+ breast cancer among women
premenopausal at blood collection (p = 0.03). Finally, we
performed sensitivity analyses after excluding breast
cancer cases diagnosed within 2 years of blood collection
(n = 370, 18%) to address potential reverse causation.
All statistical tests were two-tailed and significant at
the p < 0.05 level. SAS 9.3 (SAS Institute Inc., Cary, NC,
USA) was used for all statistical analyses.
Results
A total of 462 (23%) case-control pairs were premeno-
pausal at blood donation, whereas 1546 pairs were post-
menopausal (Table 1). Among postmenopausal women, a
total of 755 pairs (49%) were using exogenous hormones
at blood collection. Median age at baseline was 57 (10th–
90th percentiles: 45–64) years, and among cases the
median age at diagnosis was 61 (10th–90th percentiles:
50–70) years. Median time between blood collection and
diagnosis was 4.7 (10th–90th percentiles: 1.2–8.1)
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years. Of the 2008 total cases, 81% were ER+ (n = 1622;
ER–, n = 386).
Serum OPG concentrations were positively correlated
with age (r = 0.29, p < 0.01). Among premenopausal
women, OPG did not vary by menstrual cycle phase (p
= 0.29). OPG concentrations did not vary by menopausal
status at blood collection (p = 0.31). However, among
women postmenopausal at blood collection, OPG levels
differed between current users and non-users of HT (at
time of blood collection; p = 0.01), although the absolute
differences were small (adjusted geometric mean con-
centrations, ng/mL, HT non-users: 0.202 [95% CI:
0.197–0.207] vs. HT users: 0.210 [0.204–0.216]).
Among HT users, OPG levels did not further differ by
type of HT (i.e., unopposed vs. opposed estrogens; p =
0.64).
OPG concentrations were not correlated with age at
menopause, number of FTPs, BMI (kg/m2), or alcohol
consumption (g/day), nor did concentrations differ be-
tween women with and without completed FTP (data
not shown). Higher OPG concentrations were observed
in women reporting ever OC use, as compared to never
users (ng/mL, OC use, never: 0.192 [0.188–0.198]; ever
OC users: 0.198 [0.193–0.203]; p = 0.02). Among women
with additional hormone measurements available (n:
297–2008) OPG was not correlated (r < |0.14|) with en-
dogenous sex steroid hormones, IGF-I, or prolactin,
among either pre- or postmenopausal women, or within
strata of postmenopausal HT users and non-users
(Additional file 1: Table S2).
We observed significant heterogeneity in the associ-
ation between OPG and risk of ER+ vs. ER– tumors
(phet = 0.02) (Table 2). Higher concentrations of OPG
were associated with increased risk of ER– breast cancer
(top vs. bottom tertile RR =1.93 [95% CI 1.24–3.02];
ptrend = 0.03). In contrast, we observed a suggestive in-
verse association between OPG and ER+ disease (top vs.
bottom tertile RR = 0.84 [95% CI 0.68–1.04]; ptrend = 0.18).
The association between OPG and ER– disease did not
differ by menopausal status (phet = 0.97). However, we ob-
served suggestive heterogeneity by menopausal status for
ER+ disease (phet = 0.05; premenopausal, RRlog2 = 0.53
[0.31–0.88]); postmenopausal, RRlog2 = 0.97 [0.75–1.25];
Table 3). However, there was evidence of potential non-
linearity of the association between OPG and ER+ breast
cancer among women premenopausal at blood collection
(p = 0.03; Additional file 1: Figure S1), and this associ-
ation should be interpreted cautiously. We observed
no heterogeneity by HT use (among postmenopausal
women; phet ≥ 0.43) or by age at breast cancer diagnosis
(age <50 vs. 50+; phet ≥ 0.30; Table 4). Results were similar
in analyses considering both ER and PR status.
We observed no evidence for effect modification by
other reproductive and lifestyle factors (e.g., ever full-
term pregnancy, OC use, age at menopause (postmeno-
pausal women) or by levels of endogenous hormones
(e.g., estradiol, progesterone, prolactin; data not shown),
with the exception of suggestive heterogeneity by prolac-
tin concentrations for ER– disease (prolactin < median,
RR = 0.78 [0.23–2.69]; ≥ median, RR = 2.98 [1.23–7.23];
phet = 0.05) and heterogeneity by testosterone concentra-
tions for ER+ disease (testosterone <median, RR = 0.35
[0.15–0.79]; ≥ median, RR = 1.05 [0.52–2.13]; phet = 0.04).
Finally, results were similar in sensitivity analyses restricted
to women diagnosed >2 years after blood collection. OPG
demonstrated high within-person reproducibility, in terms
of the relative ranking of study participants, over
1 year (r = 0.85) and 14 years (r = 0.75).
Discussion
Higher serum osteoprotegerin (OPG) concentrations were
associated with an increased risk of ER– breast cancer,
and a modest, suggestive reduction in risk of ER+ tumors,
in this large investigation. With a total of 2008 breast can-
cer cases with documented ER status, this is the first
large-scale prospective study to address circulating OPG
Table 1 Baseline and case characteristics: EPIC cohort breast
cancer nested case-control study
Cases Controls
Full study population, n 2008 2008
Baseline characteristics, median (10th–90th percentiles) or n (%)
Age at blood collection, years 57 (45-64) 57 (45-64)
Age at menarche, years 13 (11-15) 13 (11-15)
Premenopausal 462 (23%) 462 (23%)
Postmenopausal 1546 (77%) 1546 (77%)
HT use at blood collectiona 755 (49%) 755 (49%)
Age at menopause, yearsa 50 (43-55) 50 (43-55)
Completed term pregnancy 1695 (84%) 1733 (86%)
Age at first term pregnancy,b years 25 (20-31) 24 (20-30)
BMI, kg/m2 24 (21-31) 24 (20-30)
Case characteristics
ER+ 1622 (81%)
ER– 386 (19%)
ER+/PR + c 929 (63%)
ER–/PR– 258 (17%)
Age at diagnosis, years 61 (50-70)
Time between blood donation
and diagnosis, years
4.7 (1.2-8.1)
Osteoprotegerin concentrations, ng/mL, median (10th–90th percentiles)
0.196
(0.138-0.282)
0.197
(0.141-0.289)
aAmong postmenopausal women
bAmong women with completed term pregnancy
cPR status available for 74% of cases (n = 1480); percentages represent
percentage of total cases with ER and PR status available
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and subsequent breast cancer risk by hormone receptor
subtype.
Vik et al. reported an inverse association between OPG
concentrations and breast cancer risk in a case-cohort
study of more than 6000 women and men (median 13.5-
year follow-up) [12]. This Norwegian investigation in-
cluded only 76 breast cancer cases and thus could not
address risk by hormone receptor status. Most likely, how-
ever, the majority of breast cancer cases were ER+, as this
is the predominant subtype among European women. The
suggestive inverse association between OPG and ER+
breast cancer risk observed in the current study lies in the
same direction as in this previous investigation, although
the association observed in our study is weaker. In two
analyses restricted to BRCA1/2 carriers, higher serum
OPG concentrations were associated with lower risk mu-
tation site [22] and lower breast cancer risk (n = 18 cases)
[23]. BRCA1/2 mutation status was not available in our
study population, and family history of breast cancer is
missing for the majority of participants (64%). Therefore,
we were unable to evaluate OPG and breast cancer risk
restricted to a higher risk population in our study. These
three investigations used ELISA assays, while we used
an electrochemiluminescence assay. Vik [12] and Oden
[23] observed starkly different mean/median OPG
concentrations in their two study populations (Vik,
reported mean concentration: 3.40 ng/mL; Oden, reported
median concentration, 95 ng/mL). Widschwendter et
al. [22] did not directly report mean or median OPG
concentration. To date, there is no cross-assay
standardization protocol for OPG. Thus, between-
study comparisons must rely on the within-study rela-
tive ranking of participants.
Prior investigations show high levels of OPG protein or
mRNA in a variety of breast cancer cell lines [3, 6, 24–27],
with lower levels in primary human mammary epithelial
cells [6]. Studies of primary breast tumors also showed
variable degrees of OPG protein [3, 6, 24, 28–30] or
mRNA expression [30–34]. In larger patient series, immu-
nohistochemical analyses [24, 29, 35] indicated OPG pro-
tein in 40-45% of invasive primary tumors, an inverse
association between OPG expression and tumor grade
and stage, and a positive association with ER status
[24, 29, 30]. Studies based on mRNA analysis, how-
ever, showed a positive [36], a negative [33, 34], or
no association [32] between the gene expressions for
OPG and ER status. A limited number of studies have
examined non-neoplastic mammary tissue. On bal-
ance, these investigations observed some level of OPG
expression, however, at lower levels than that observed in
breast tumor tissue [6, 29, 31, 37]. In a large, multicenter
analysis of more than 4500 patients, higher OPG
mRNA expression was associated with reduced breast
cancer-specific mortality among patients with ER+ tumors
(n = 1941), but not among patients with ER– disease
(n = 649) [33]. These observations support a role for
OPG in breast tumor development and prognosis, with
potential differences between ER- and ER+ disease.
Table 2 Circulating concentrations of osteoprotegerin and breast cancer risk by hormone-receptor subtype: EPIC cohort breast
cancer nested case-control study
Tertiles
1 2 3
Cut points (ng/mL) <0.18 0.18 - <0.22 ≥0.22 ptrend
a RRlog2
b phet
c
ER+/PR+
Cases/controls 342/312 297/308 290/309
RR (95% CI) Ref. 0.84 (0.65-1.07) 0.81 (0.61-1.08) 0.27 0.85 (0.63-1.14) 0.02
ER+
Cases/controls 559/510 519/544 544/568
RR (95% CI) Ref. 0.84 (0.70-1.02) 0.84 (0.68-1.04) 0.18 0.86 (0.68-1.08) 0.02
ER–/PR–
Cases/controls 82/96 78/96 98/66
RR (95% CI) Ref. 1.12 (0.68-1.83) 2.39 (1.35-4.23) 0.04 1.89 (1.03-3.47)
ER–
Cases/controls 139/160 117/125 130/101
RR (95% CI) Ref. 1.22 (0.83-1.83) 1.93 (1.24-3.02) 0.03 1.69 (1.05-2.74)
Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first
full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
aptrend based on log2-transformed OPG concentration
bRR for a one-unit change in log2-transformed OPG
cpheterogeneity comparing ER+/PR+ to ER–/PR– and ER+ to ER– subtypes, based on log2-transformed OPG concentration
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We observed increased risk of ER– (and ER–/PR–)
breast cancer among women with higher serum OPG
concentrations. OPG binding to TRAIL represents one
key mechanism through which OPG could promote
breast tumor development, particularly of ER– tumors
[8, 38]. TRAIL is highly homologous to tumor necrosis
factors (TNFs), and induces apoptosis through specific
TRAIL receptors in a diverse range of cell lines, and
preferentially in cancer cells [39]. Analyses in breast can-
cer cell lines have shown that triple-negative cells (i.e.,
ER–/PR–/HER2–) are especially sensitive to TRAIL-
induced apoptosis, whereas sensitivity to TRAIL varies
across different HER2+ cell lines, and is systematically
absent among ER+ cells [7]. Our study population
Table 3 Circulating concentrations of osteoprotegerin and breast cancer risk by menopausal status at blood collection: EPIC cohort
breast cancer nested case-control study
Tertiles
1 2 3
Cut points (ng/mL) <0.18 0.18 - <0.22 ≥0.22 ptrend
a RRlog2
c phet
d
Hormone receptor positive cases
Premenopausal
ER+/PR+
Cases/controls 168/152 61/77 24/24
RR (95% CI) Ref. 0.67 (0.43-1.04) 0.89 (0.42-1.87) 0.07 0.58 (0.32-1.05) 0.36
ER+
Cases/controls 236/200 79/118 37/34
RR (95% CI) Ref. 0.55 (0.38-0.81) 0.85 (0.47-1.55) 0.01b 0.53 (0.31-0.88)b 0.05b
Postmenopausal
ER+/PR+
Cases/controls 174/160 236/231 266/285
RR (95% CI) Ref. 0.92 (0.68-1.24) 0.85 (0.61-1.17) 0.73 0.94 (0.66-1.33)
ER+
Cases/controls 323/310 440/426 507/534
RR (95% CI) Ref. 0.98 (0.78-1.22) 0.91 (0.72-1.15) 0.79 0.97 (0.75-1.25)
Hormone receptor negative cases
Premenopausal
ER–/PR–
Cases/controls 35/44 18/17 14/6
RR (95% CI) Ref. 1.60 (0.57-4.44) 3.77 (0.86-16.4) 0.25 2.01 (0.60-6.70) 0.87
ER–
Cases/controls 59/70 30/30 21/10
RR (95% CI) Ref. 1.42 (0.67-2.99) 3.21 (1.17-8.85) 0.26 1.63 (0.70-3.84) 0.97
Postmenopausal
ER–/PR–
Cases/controls 47/52 60/79 84/60
RR (95% CI) Ref. 1.02 (0.55-1.89) 2.03 (1.03-3.98) 0.14 1.76 (0.82-3.77)
ER–
Cases/controls 80/90 87/95 109/91 0.12 1.62 (0.88-2.96)
RR (95% CI) Ref. 1.14 (0.68-1.90) 1.60 (0.95-2.69)
Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first
full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
aptrend based on log2-transformed continuous variable
bEvidence of non-linear association, p = 0.03; see Additional file 1: Figure S1
cRR for a one-unit change in log2-transformed OPG
dpheterogeneity comparing women premenopausal to postmenopausal at blood collection based on RRlog2; among postmenopausal women, results did not differ
by HT use at blood collection (p ≥ 0.43)
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included only 58 triple-negative cases, and we observed
no association in this subgroup. We observed a stronger
association between OPG and ER– breast cancer risk
among women with relatively high circulating prolactin
concentrations. Prolactin inhibits TRAIL-induced apop-
tosis in hormone (androgen)-insensitive PC3 prostate
cancer cells [40]. To our knowledge there are no data on
prolactin and TRAIL in breast cancer; however, prolactin
inhibition has been shown to increase apoptosis in
breast cancer cell lines [41], and prolactin interferes with
the apoptotic effect of cisplatin chemotherapy [42].
We observed a suggestive inverse association between
OPG and ER+ breast cancer. OPG may reduce breast
tumor development through binding to RANKL. In
addition to regulating bone turnover, RANK and RANKL
mediate progesterone- and prolactin-induced changes in
the mammary gland, including the expansion of
mammary epithelial stem cells [43], proliferation of the
mammary epithelium [44, 45], and the development of a
lactating mammary gland during pregnancy [46]. Further-
more, experimental animal studies have demonstrated
that increased expression of RANKL in PR+ luminal epi-
thelial cells, following autocrine and paracrine stimulation
of RANK signaling in both receptor positive and negative
epithelial cells, is a mechanism mediating progestin-driven
mammary carcinogenesis [43, 44, 47, 48]. Circulating
OPG may modulate these effects, with one investigation
showing increased mammary epithelial proliferation after
intravenous administration of soluble RANKL (sRANKL),
and inhibition of proliferation by the administration of
OPG, in an animal model [44]; in vitro investigations of
administered RANKL and OPG in human breast tumor
samples show similar results [49]. It is conceivable that
OPG inhibits the development of ER+/PR+ breast tumors
Table 4 Circulating concentrations of osteoprotegerin and breast cancer risk by age at diagnosis: EPIC cohort breast cancer nested
case-control study
Tertiles
1 2 3
Cut points (ng/mL) <0.18 0.18 - <0.22 ≥0.22 ptrend
a RRlog2
b phet
c phet
d
Age at diagnosis
<50 yearse
ER+/PR+
Cases/controls 82/70 25/35 13/15
RR (95% CI) Ref. 0.48 (0.23-0.98) 0.53 (0.17-1.69) 0.14 0.48 (0.18-1.28)
ER+
Cases/controls 99/87 27/40 17/16
RR (95% CI) Ref. 0.49 (0.25-0.96) 0.79 (0.30-2.09) 0.32 0.64 (0.26-1.54)
≥50 years
ER+/PR+
Cases/controls 260/242 272/273 277/294
RR (95% CI) Ref. 0.90 (0.69-1.18) 0.86 (0.64-1.16) 0.47 0.89 (0.65-1.22) 0.02 0.53
ER+
Cases/controls 460/423 492/504 527/552
RR (95% CI) Ref. 0.87 (0.71-1.06) 0.85 (0.68-1.06) 0.24 0.87 (0.68-1.10) 0.02 0.72
ER–/PR–
Cases/controls 58/71 71/90 95/63
RR (95% CI) Ref. 1.15 (0.65-2.02) 2.54 (1.35-4.77) 0.02 2.21 (1.11-4.40) 0.30
ER–
Cases/controls 101/119 103/112 123/96
RR (95% CI) Ref. 1.21 (0.77-1.92) 1.90 (1.17-3.09) 0.04 1.76 (1.03-3.01) 0.62
Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first
full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
aptrend based on log2-transformed continuous variable
bRR for a one-unit change in log2-transformed OPG
cpheterogeneity comparing ER+/PR+ to ER–/PR– and ER+ to ER– subtypes, based on RRlog2
dpheterogeneity comparing age at diagnosis <50 to 50+ years based on RRlog2
eAge at diagnosis results limited to ER+/PR+ and ER+ cases given n = 34 ER–/PR– cases; n = 59 ER– cases in this subgroup
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by interfering with the growth-promoting effects of
RANKL, which depend on PR-mediated local synthesis.
Breast cancer risk increases with higher lifetime number
of menstrual cycles, an indicator for cumulative exposure
to luteal phase progesterone levels, and is also increased
among postmenopausal women using combined estrogen-
plus-progestin HT [50–52]. Interestingly, RANKL expres-
sion in both normal and malignant breast tissue is also
increased during the luteal phase of the menstrual cycle
[53] and in combined HT users [54]. We observed no indi-
cation that the association of serum OPG concentrations
with breast cancer risk varied between tumors diagnosed
before or after age 50 (the median age at menopause in
EPIC), by age at menopause, or between users and non-
users of HT.
While several tissue types produce OPG, bone marrow
cells and vascular endothelial cells may be the predom-
inant sources of circulating OPG [55–57]. Estrogens,
vitamin D3, and growth hormone promote OPG synthe-
sis in vitro (e.g., by osteoblasts) [55, 58, 59]. Limited
cross-sectional data in women support no, or only mod-
est, associations between circulating hormones (e.g., es-
tradiol [60], progesterone [22]) and OPG in healthy
women. As in other recent studies [22, 61], we observed
no systematic variation of serum OPG concentration
with phase of menstrual cycle or with menopausal status
(after adjustment for age at blood collection) [62], and a
gradual rise of OPG levels with increasing age [58, 62,
63]. Prior studies provide mixed results on whether post-
menopausal HT use is associated with OPG [64–66].
We observed somewhat higher OPG concentrations
among postmenopausal women using HT, with no differ-
ences by HT type (i.e., opposed vs. unopposed estrogens).
In subgroup analyses, where additional measurements of
endogenous hormones were available, we observed no
correlations between OPG and DHEAS, androstenedione,
testosterone, estradiol, IGF-I, or prolactin.
Conclusions
In summary, recent research has revealed intriguing paral-
lels in the roles for OPG and the RANK/RANKL axis in
bone metabolism and in mammary gland physiology. Our
large-scale investigation is the first to document potentially
diverse associations of OPG with risks of ER– or ER+
breast cancer. There is increasing interest in denosumab—
a humanized antibody that blocks RANKL signaling, which
is used routinely to treat osteoporosis — as a drug for pre-
venting breast cancer recurrence among women with early
stage breast cancer and primary prevention in high risk
women [67]. Although the role of OPG in breast cancer is
complex, due to its possible interactions with both TRAIL
and RANKL, our data may provide indirect insight into
the possible benefits or risks potentially associated with
treatments targeting the RANK/RANKL system.
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